First Trust Advisors
TPTX

First Trust Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

First Trust Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,178
Closed -$6.11M – 2486
2020
Q4 		$6.11M Buy
50,178
+10,266
+26% +$1.12M 0.01% 1017
2020
Q3 		$3.49M Buy
+39,912
New +$2.78M 0.01% 1105

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

First Trust Advisors's TPTX Position: Q1 2021 in Review

First Trust Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2021, closing a stake of 50,178 shares — an estimated $6.11M sold.

First Trust Advisors first reported a position in TPTX in Q3 2020 and held it in 2 quarters. The position peaked at $6.11M in Q4 2020. 202 funds tracked by Wall St. Rank hold TPTX as of Q1 2021.

  • First Trust Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • First Trust Advisors sold 50,178 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $6.11M.
  • First Trust Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • First Trust Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $6.11M in Q4 2020.
  • 202 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2021.

Based on First Trust Advisors's 13F filing for Q1 2021, filed 14 May 2021.